2 ELIGIBILITY ASSESSMENT AND ENROLLMENT ELIGIBILITY CRITERIA 2.1.1 Inclusion Criteria a. Metastatic melanoma or epithelial cancer with at least one le sion that is resectable or in selected cases, available PBMCs. b. Measurable and evaluable metastatic disease per RECIST 1.1 cr iteria. c. Confirmation of the diagnosis of m etastatic cancer by the Labo ratory of Pathology of NCI. d. All patients must be refractor y to approved standard systemic therapy. e. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with st ereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible . f.$JH \HDUVDQG\HDUV Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 13g. Clinical performan ce status of ECOG 0, 1, 2.